As I see it

Share this article:
There's a generational element to the failure of the Obama administration's much-hyped agenda to increase transparency at government agencies like FDA, where reform has been submerged by bureaucratic resistance.
Restrictions on access to public information in government agencies began secretly infiltrating official Washington 12-15 years ago; today they are a virtual straitjacket on what can be known. Efforts to gain access now run into the age barrier. If you're under 35-45 you've known nothing else and think the status quo is the way it's meant to be.
Washington's Politico reported in March that President Obama quietly accepted a “transparency” award from the open government community—in a closed, undisclosed meeting at the White House. The people who presented the award doubtless belong to the same youthful generation who apparently saw the President's inaugural “open government” messages to federal offices as laudable landmarks, without checking to verify their effectiveness two years later.
As this blissful bout of inside-the-Beltway celebrations among mutually inter-dependent back-slappers was going on, FDA announced the departure after one year of its beleaguered associate commissioner for external affairs, Beth Martino.
Her time at the agency had seen a rising chorus of protests from (older) journalists about FDA press office “censorship” and a ban on advance research among outside experts when the agency issues an embargoed news release. She stunned protesting journalists by telling them: “I haven't heard any complaints.” In Washington, the hear-only-what-you-want-to-hear crowd is in charge.
James G. Dickinson is editor of Dickinson's FDA Webview (
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications